Rapport Therapeutics: Citizens JMP sees 217% price potential and references the study evaluating RAP-219 in focal epilepsy

Rapport Therapeutics (RAPP) presented its third quarter report on November 6. The company's outlook is primarily based on its leading product candidate RAP-219 and a strongly secured capital base that mitigates development risks over the coming years. The Path to Phase 3 in Epilepsy The central value driver for Rapport Therapeutics is currently the leading product candidate RAP-219, a potential first-in-class modulator developed using the proprietary RAP platform to achieve neuroanatomical specificity. Investors are particularly focused on the...